Gilead Sciences stock rises 1.55% and outperforms competitors
Updated
Updated · MarketWatch · Apr 30
Gilead Sciences stock rises 1.55% and outperforms competitors
11 articles · Updated · MarketWatch · Apr 30
Shares closed at $130.84 on Thursday as the S&P 500 gained 1.02% to 7,209.01 and the Dow rose 1.62% to 49,652.14.
Gilead remained 16.82% below its 52-week high of $157.29 reached on 11 February, while trading volume of 6.5 million topped its 50-day average of 6.1 million.
Among peers, Johnson & Johnson rose 1.10%, Pfizer gained 1.68% and Abbott Laboratories fell 0.59%, leaving Gilead with mixed relative performance despite beating some competitors.
Can Gilead's multi-billion dollar pivot to oncology successfully replace its aging HIV empire, or is it too risky a gamble for investors?
With new long-acting rivals emerging, can Gilead's blockbuster HIV franchise maintain its market dominance through the next decade?